ISPH Short I think there is a valid short opportunity here.
Here is more fundamental analysis (done by ChatGPT).
///////////////////////////////////////////////////////////////////////////////
Ibnsina Pharma is a prominent pharmaceutical distribution company in Egypt, listed on the Egyptian Exchange under the ticker symbol ISPH. Established in 2001, the company distributes a wide range of pharmaceutical and cosmetic products to both private and public-sector clients, including pharmacies, hospitals, and healthcare institutions.
INVESTING.COM
Financial Overview:
Revenue: In 2023, Ibnsina Pharma reported revenues of approximately EGP 33.95 billion.
BARRONS.COM
Net Income: The net income for the same period was EGP 173.14 million, resulting in a net profit margin of 0.51%.
BARRONS.COM
Total Assets and Liabilities: The company's total assets stood at EGP 18.55 billion, with total liabilities amounting to EGP 17.1 billion, indicating a debt-to-assets ratio of 92.19%.
BARRONS.COM
Shareholder Structure:
Ibnsina Pharma's ownership is diversified among prominent entities:
Free Float: 40.7%
Abdel Gawad Family: 15.0%
Faisal Islamic Bank: 14.0%
Mahgoub Family: 12.9%
European Bank for Reconstruction and Development (EBRD): 9.6%
Blom Investment: 7.8%
This diverse shareholder base has enhanced the company's corporate governance practices.
IR.IBNSINA-PHARMA.COM
Stock Performance:
As of January 29, 2025, the stock closed at EGP 7.02 per share, with a 52-week range between EGP 2.14 and EGP 7.59.
IR.IBNSINA-PHARMA.COM
Considerations for Investors:
While Ibnsina Pharma has demonstrated significant revenue generation, its net profit margin is relatively low, and the company operates with a high debt-to-assets ratio. Potential investors should weigh these factors carefully and consider consulting with a financial advisor to determine if this investment aligns with their risk tolerance and financial objectives.
